Alzheimer's disease
AbbVie to buy Alzheimer's therapy developer Aliada for US$1.4 billion
The Aliada deal is expected to close by the end of this year
What you should know about the newest Alzheimer’s drugs
While humans are living longer – a child born in 2021 on average could expect to live to 71 – we have not figured out how to beat one of the worst scourges of aging: Alzheimer’s disease.
Lilly Alzheimer drug faces more delays as FDA plans hearing
Eli Lilly’s Alzheimer’s disease drug donanemab faces further delays in gaining approval, with US regulators planning to hold a hearing of external advisers to explore how safe the therapy is and how w...
Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More
